Stemline's Elzonris get FDA nod, first therapy for rare blood disorder

FDA approved Elzonris tagraxofusp-erzs (SL-401) from Stemline Therapeutics Inc. (NASDAQ:STML) to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN) in patients ages two

Read the full 222 word article

User Sign In